Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics (Q36184067)

12 August 2017

Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics (English)

1 reference

12 August 2017

1 reference

Carlotta Pozza

1

0 references

Andrea M. Isidori

object named as

Andrea M Isidori

5

0 references

Andrea Lenzi

object named as

Andrea Lenzi

4

0 references

author name string

Chiara Graziadio

2

1 reference

PMCID

3425913

12 August 2017

Elisa Giannetta

3

1 reference

12 August 2017

9 August 2012

1 reference

12 August 2017

1 reference

12 August 2017

2012

1 reference

12 August 2017

685213

1 reference

Creative Commons Attribution 3.0 Unported

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Advances in medical therapies for Cushing's syndrome.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

A new medical therapy for Cushing disease?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

New targeted therapies in pituitary carcinoma resistant to temozolomide

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Everolimus for advanced pancreatic neuroendocrine tumors.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Pituitary tumors in 2010: a new therapeutic era for pituitary tumors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Medical treatment of Cushing's disease: Overview and recent findings

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Dopamine agonists and valvular heart disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Adjuvant mitotane treatment for adrenocortical carcinoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

PPAR-gamma in Cushing's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

The Nelson's syndrome... revisited

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Clinical review: Diagnosis and management of pituitary carcinomas.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Diagnosis and complications of Cushing's syndrome: a consensus statement.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Corticotroph pituitary carcinoma: case report and literature review

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Retinoic acid prevents experimental Cushing syndrome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Therapy of Cushing's syndrome with steroid biosynthesis inhibitors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Dopamine receptor expression and function in corticotroph ectopic tumors.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

A Pituitary Parasellar Tumor with Extracranial Metastases and High, Partially Suppressible Levels of Adrenocorticotropin and Related Peptides*

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

Mitotane increases the blood levels of hormone-binding proteins

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

2 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus-pituitary-adrenal system in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Merits and pitfalls of mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Dopamine receptor expression and function in corticotroph pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Crooke's hyalinization in silent corticotroph adenoma: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Diurnal ACTH and plasma cortisol variations in healthy dogs and in those with pituitary-dependent Cushing's syndrome before and after treatment with retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F685213

Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425913

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors

23 September 2018

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas removed from patients with Nelson's syndrome

1 reference

12 December 2020

The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo

1 reference

12 December 2020

Aminoglutethimide and metyrapone in the management of Cushing's syndrome

1 reference

12 December 2020

The Mechanism of the Suppressive Action of Bromocriptine on Adrenocorticotropin Secretion in Patients with Cushing′s Disease and Nelson′s Syndrome*

1 reference

12 December 2020

Effect of injectable bromocriptine in patients with Cushing's disease

1 reference

12 December 2020

The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome

1 reference

12 December 2020

Bromocriptine in Nelson's syndrome and Cushing's disease

1 reference

12 December 2020

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/685213

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

PMCID

3425913